<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="56864">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01708733</url>
  </required_header>
  <id_info>
    <org_study_id>101001-62-010</org_study_id>
    <nct_id>NCT01708733</nct_id>
  </id_info>
  <brief_title>The Effect of Chinese Herbal Formula (KSY) on HCV Carrier With Abnormal Liver Function</brief_title>
  <official_title>An Evaluation of the Extract of KUAN SIN YIN on Hepatitis C: a Randomized, Double-blinded and Placebo-controlled Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei City Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei City Hospital</source>
  <oversight_info>
    <authority>Taiwan: Department of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to examine whether the Chinese herbal formula (KSY) is effective on
      HCV Carrier With Abnormal Liver Function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      percentage of change on HCV RNA titer and liver function (GPT).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>HCV RNA titer</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum GPT level</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>WHOQOL-BREF</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Liver Function</condition>
  <arm_group>
    <arm_group_label>KSY diluted</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>KSY diluted, 100mg decoction by mouth per day for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KSY</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KSY, 100mg decoction by mouth per day for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KSY</intervention_name>
    <description>Chinese herbal formula</description>
    <arm_group_label>KSY</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  40 &lt; GPT &lt;200 HCV carrier Age: 18-65 yrs old

        Exclusion Criteria:

          -  Creatinine &gt;2.0 mg/dL Total bilirubin &gt; 2.0mg/dL Not suitable patients diagnosis by
             physician in charge.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Taipei City Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>886</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 28, 2014</lastchanged_date>
  <firstreceived_date>October 15, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Taipei City Hospital</investigator_affiliation>
    <investigator_full_name>Chung-Hua Hsu</investigator_full_name>
    <investigator_title>chief medical officer</investigator_title>
  </responsible_party>
  <keyword>HCV carrier</keyword>
  <keyword>Chinese herbal medicine</keyword>
  <keyword>Liver function</keyword>
  <keyword>HCV RNA titer</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
